izpis_h1_title_alt

Targeting the formation of estrogens for treatment of hormone dependent diseases–current status
ID Lanišnik-Rižner, Tea (Author), ID Romano, Andrea (Author)

.pdfPDF - Presentation file, Download (1,20 MB)
MD5: 2D3C26DD14C776129BBA51EFB373317C
URLURL - Source URL, Visit https://www.frontiersin.org/articles/10.3389/fphar.2023.1155558/full This link opens in a new window

Abstract
Local formation and action of estrogens have crucial roles in hormone dependent cancers and benign diseases like endometriosis. Drugs that are currently used for the treatment of these diseases act at the receptor (i.e., they interfere with the hormone receptor) and at the pre-receptor levels, targeting the local formation of estrogens. Since 1980s the local formation of estrogens has been targeted by inhibitors of aromatase that catalyses their formation from androgens. Steroidal and non-steroidal inhibitors have successfully been used for treatment of postmenopausal breast cancer and have also been evaluated in clinical studies in patients with endometrial, ovarian cancers and endometriosis. In the last decade also inhibitors of sulfatase that catalyses the hydrolysis of inactive estrogen-sulfates entered clinical trials for treatment of breast, endometrial cancers and endometriosis, with clinical effects seen in breast cancer especially. More recently, inhibitors of 17beta-hydroxysteroid dehydrogenase 1, an enzyme responsible for formation of the most potent estrogen, estradiol, have shown promising results in preclinical studies and have already entered clinical evaluation for endometriosis. This review aims to overview the current status on the use of hormonal drugs for the main hormone-dependent diseases. Further, it aims to explain the mechanisms behind the -sometimes- observed weak effects and low therapeutic efficacy of these drugs and the opportunity and the advantages of combined treatments targeting several enzymes in the local estrogen formation, or drugs acting with different therapeutic mechanism.

Language:English
Keywords:intracrinology, endometrial cancer, prostate cancer, estrogens, breast cancer, ovarian cancer, endometriosis
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:16 str.
Numbering:Vol. 14, art. 1155558
PID:20.500.12556/RUL-153999 This link opens in a new window
UDC:618.1
ISSN on article:1663-9812
DOI:10.3389/fphar.2023.1155558 This link opens in a new window
COBISS.SI-ID:150180099 This link opens in a new window
Publication date in RUL:18.01.2024
Views:127
Downloads:15
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Frontiers in pharmacology
Shortened title:Front Pharmacol
Publisher:Frontiers Media
ISSN:1663-9812
COBISS.SI-ID:29551833 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:nosečnice, intrakrinologija, rak endometrija, rak prostate

Projects

Funder:ARRS - Slovenian Research Agency
Project number:J3-1755
Name:Biokemijski označevalci endometrioze: študije transkriptoma in proteoma

Funder:ARRS - Slovenian Research Agency
Project number:J3-2535
Name:Vloga androgenov pri hormonsko odvisnih boleznih: pomen za diagnostiko in zdravljenje

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back